Morgen, E K
Lenz, H-J
Jonker, D J
Tu, D
Milano, G
Graziano, F
Zalcberg, J
Karapetis, C S
Dobrovic, A
O’Callaghan, C J
Liu, G
Article History
Received: 29 May 2015
Revised: 23 May 2016
Accepted: 15 June 2016
First Online: 29 November 2016
Competing interests
: H-JL: advisory board member for Merck KG, Bristol Myers Squibb clinical trial support, Merck Serono and Bristol Myers Squibb. GM: Merck Serono honorarium. JZ: travel and research support to Merck Serono. CSK: advisory board member for Amgen and Merck Serono. AD: advisory board member for Amgen. GL: advisory board member for Roche, Astra Zeneca, Novartis, Pfizer and Merck Serono. The remaining authors declare no conflict of interest.